Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly completes acquisition of SGX Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Lilly has completed the acquisition of SGX Pharmaceuticals, the San-Diego based biotechnology company focused on oncology. A majority of SGX shareholders voted in favour of the merger agreement with Lilly. Under the agreement, Lilly acquires all outstanding shares of SGX common stock at $3.00 per share. All other closing conditions have been met. Lilly and SGX have been in partnership since 2003 to explore three-dimensional structures of Lilly's drug targets using SGX's X-ray crystallography technology (Scrip Online, July 9th, 2008).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts